Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Mitigating phospholipid peroxidation of macrophages in stress-induced tumor microenvironment by natural ALOX15/PEBP1 complex inhibitors".
Luo X, Li DD, Li ZC, Li ZX, Zou DH, Huang F, Wang G, Wang R, Cao YF, Sun WY, Kurihara H, Liang L, Li YF, Jin W, Wu YP, He RR. Luo X, et al. Among authors: li yf. Phytomedicine. 2024 Nov 9:156207. doi: 10.1016/j.phymed.2024.156207. Online ahead of print. Phytomedicine. 2024. PMID: 39523159 No abstract available.
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial.
Liu SL, Li XY, Yang JH, Wen DX, Guo SS, Liu LT, Li YF, Luo MJ, Xie SY, Liang YJ, Sun XS, Yang ZC, Lv XF, Luo DH, Li JB, Liu Q, Wang P, Guo L, Mo HY, Sun R, Yang Q, Lan KQ, Jia GD, Li R, Zhao C, Xu RH, Chen QY, Tang LQ, Mai HQ. Liu SL, et al. Among authors: li yf. Lancet Oncol. 2024 Nov 7:S1470-2045(24)00504-7. doi: 10.1016/S1470-2045(24)00504-7. Online ahead of print. Lancet Oncol. 2024. PMID: 39522541
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated non-small cell lung cancer patients.
Weng CD, Liu KJ, Jin S, Su JW, Yao YH, Zhou CZ, Li YF, Chen ZX, Chen HJ, Li YY, Tang KJ, Yang JJ. Weng CD, et al. Among authors: li yf. Transl Lung Cancer Res. 2024 Oct 31;13(10):2538-2548. doi: 10.21037/tlcr-24-358. Epub 2024 Oct 28. Transl Lung Cancer Res. 2024. PMID: 39507030 Free PMC article.
3,279 results